A rapidly growing investment opportunity on a global scale

Worldwide Healthcare Trust PLC (WWH) is an LSE-listed investment company seeking to provide investors with a globally diversified exposure to a portfolio of world-class healthcare companies.

The investment manager, OrbiMed, is the world’s largest dedicated healthcare investment company with an ever-growing team of sector specialists who are focused on identifying the world’s most innovative healthcare companies across a range of sub-sectors and geographies. The portfolio includes an exposure to some of the world’s largest pharmaceutical companies alongside those at the smaller end of the spectrum, such as early-stage biotechnology companies. All of them strive to address unmet medical needs and enhance human lives. 

Find out more about us

Diagram demonstrating WWH’s global healthcare spend of >$10 trillion, split into 6 sectors and encompassed by artificial intelligence. Sector 1: Bio-pharma: 52 Novel FDA approvals in 2025; 57% Reduction in all-cause mortality for Lilly’s GLP-1 Foundayo; $73bn WW Sales of GLP-1 medicines in 2025. Sector 2: Healthcare services: 1.4bn people aged 60+ by 2030, the key driver for health care services; +72% The average savings of TrumpRx.gov, the new direct-to-patient pharmacy; 56.1mn a American seniors who will get $50 co-pay access to GLP-s in 2026. Sector 3: Medical Technology: 3.1mn Da Vinci robot procedures performed in 2025; 1,300 AI-enabled medical devices authorized by FDA; $1+bn FARAPULSE first-year sales in the US. Sector 4: Diagnostics: 12% CAGR for Liquid Biopsy growth to 2030; 266,000 federally certified labs in the US; 2/3 US adults 45+ screened for colorectal cancer. Sector 5: Lifescience Tools: 14 billion Clinical lab tests and blood screens conducted in the US in 2025; 250 Targeted oncology agents approved in the US, creating constant manufacturing demand; $150 New low cost continues to expand the total addressable market for genomics. Sector 6: Emerging markets: 30.5% of Global Pipelines from China-based biopharma companies; $138bn in China Out-licenced clinical assets; 2x increase in prescription drugs sales in India by 2030.

Worldwide Healthcare Trust (WWH) – Investor Update Webinar

Listen to Portfolio Managers, Trevor Polischuk and Sven H. Borho, provide investors with an update on WWH's recent performance and how the portfolio is positioned to try and take advantage of the current long-term opportunities across the global healthcare sector.

28 April 2026

More insights

Investor hub

Factsheets

30 Apr 2026
31 Mar 2026

Documents

12 Nov 2025
10 Jun 2025

How to Invest

The Company’s shares are traded openly on the London Stock Exchange and can be purchased through a stockbroker, investment platform or other financial intermediary.

How to Invest

Research

To read the latest research notes that provide a timely insight into WWH, please click on the link below.

Worldwide Healthcare Trust PLC at a glance

£1,470.6m

Our net asset value

0.2%

Five-year share price (total return)*

2.4p

Dividends per share

Source: Frostrow Capital LLP

*As at 31 March 2025

Latest insights

See the latest insights from Worldwide Healthcare Trust PLC.

30 May 2026

Winterflood WWH Research Note - Finding the Cure

28 Apr 2026

Investor Update Webinar – April 2026

02 Dec 2025

Edison WWH Report: Strong H126 performance amid sector recovery - Dec 2025

Register for email alerts

Read the latest Regulatory News Service (RNS) announcements from Worldwide Healthcare Trust PLC.

Register for factsheet alerts

Sign up to the Worldwide Healthcare Trust PLC mailing list for our monthly factsheet.